Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of evodiamine in preparation of medicaments for treating alzheimer disease

A technology for Alzheimer's disease and evodiamine, which is applied in the field of medicine, can solve the problems of unreported use in Alzheimer's disease, and achieve good therapeutic effect

Inactive Publication Date: 2010-09-15
INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Evodiamine, molecular formula: C19H17N3O, exists in the fruit of Rutaceae plant Evodiamine, its structure and related biological activities have been reported in published literature, but the use of evodiamine as a treatment for Alzheimer's disease has not been seen so far to report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Improvement of learning and memory ability of Alzheimer's disease mouse model by treatment with evodiamine

[0010] Evodiamine and placebo were given to Alzheimer's disease model mice at a dose of 100 mg / kg body weight / day. The mice in the control group were given placebo only. After continuous administration for 3 months, the water maze experiment was used to verify the improvement of the learning and memory ability of the Alzheimer's disease mice. The results showed that compared with the control group, the learning and memory abilities of the mice in the administration group were significantly improved. It is proved that evodiamine treatment can improve the learning and memory ability of Alzheimer's disease mice.

Embodiment 2

[0012] Evodiamine treatment inhibits the overexpression of inflammation-related cytokines in brain tissue of Alzheimer's disease mouse model

[0013] Evodiamine and placebo were given to Alzheimer's disease model mice at a dose of 100 mg / kg body weight / day. The mice in the control group were given placebo only. After continuous administration for 3 months, the levels of cytokines IL-1β, IL-6, and TNF-α in the brain tissue of mice in the control group were significantly higher than those in wild mice detected by ELISA, while those in the brain tissue of mice in the treatment group Compared with the control group, the above cytokines decreased, which proved that evodiamine treatment could inhibit the inflammatory response in the brain tissue of Alzheimer's disease mice.

Embodiment 3

[0015] Inhibition of Cyclooxygenase-2 Expression by Evodiamine Treatment in a Mouse Model of Alzheimer's Disease

[0016] Evodiamine and placebo were given to Alzheimer's disease model mice at a dose of 100 mg / kg body weight / day. The mice in the control group were given placebo only. After continuous administration for 3 months, the expression of cyclooxygenase-2 in the brain tissue of mice in the treatment group decreased compared with that in the control group detected by Western Blotting. It is proved that evodiamine has the effect of inhibiting the inflammatory response of the central nervous system. Since the inflammatory response is one of the main reasons for the pathological development of Alzheimer's disease, evodiamine has the effect of treating Alzheimer's disease.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicaments, and provides the application of evodiamine in preparation of medicaments for treating alzheimer disease. The evodiamine can improve main symptoms of alzheimer disease, namely loss of learning and memory capability. The delay of the progression of alzheimer disease is mainly realized by: 1, inhibiting excessive activation of microglia in brain tissues, and lowering over-expression of cytokines IL-1, IL-6 and TNF-alpha; and 2, lowering expression of cycloxygenase-2, and inhibiting an inflammatory reaction of the central nervous system. Researches of curative effect and molecular mechanism on the evodiamine treating alzheimer disease prove that the evodiamine has quite good treating effect and has huge potential of becoming a clinical treatment medicament.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of evodiamine in the preparation of medicine for treating Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disease. The main manifestations are cognitive dysfunction, formation of senile plaques in brain tissue, neurofibrillary tangles and loss of neurons. Evodiamine, molecular formula: C19H17N3O, exists in the fruit of Rutaceae plant Evodiamine, its structure and related biological activities have been reported in published literature, but the use of evodiamine as a treatment for Alzheimer's disease has not been seen so far reports. Contents of the invention [0003] The main purpose of the present invention is to provide the application of evodiamine in the preparation of medicine for treating Alzheimer's disease. [0004] The evodiamine can improve the main symptoms of Alzheimer's di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P25/28
CPCA61K31/519A61P25/28
Inventor 张连峰秦川袁树民王书美
Owner INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com